Thermo Fisher Scientific Inc (TMO)
524.05
+7.36
(+1.42%)
USD |
NYSE |
Dec 20, 16:00
523.70
-0.35
(-0.07%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 200.45B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.16% |
| Valuation | |
| PE Ratio | 32.86 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.759 |
| Price to Book Value | 4.092 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.39 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7208 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 35.07% |
Profile
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%). |
| URL | https://www.thermofisher.com |
| Investor Relations URL | https://ir.thermofisher.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Oct. 23, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 13, 2024 |
Ratings
Profile
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%). |
| URL | https://www.thermofisher.com |
| Investor Relations URL | https://ir.thermofisher.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Oct. 23, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 13, 2024 |